Back to results
US 2021/0108210 A1Published application
Mucosal healing promoter
AssigneeStelic Institute & Co.
InventorsHiroyuki YONEYAMA, Masato Fujii
Life of this patent
Estimating the term…
Abstract
From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.
Claims10
1-6. (canceled)
A method of treating a chronic inflammatory disease, which is Crohn's disease or ulcerative colitis, comprising:
- endoscopically detecting an inflammatory fibrotic lesion in a rectum of a human subject;
- and
- administering locally in a submucosa of the inflammatory fibrotic lesion in the rectum of the human subject a therapeutically effective amount of an siRNA, using an endoscope,
- wherein the siRNA comprises a structure in which an RNA of SEQ ID NO:
- 3 is hybridized to an RNA of SEQ ID NO:
- 4, and the administering of the siRNA suppresses CHST15 gene expression in the human subject such that mucosal healing of the endoscopic lesion is achieved at an endoscopic level.
3 more elements
Dependencies are inferred from the claim text.